Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Pediatric Leukemia Pioneer Emil J. Freireich Dies at 93

February 2nd 2021

February 2, 2021 - Emil J. Freireich, MD, DSc, a founding father of modern clinical cancer research and the 2015 Giants of Cancer Care award winner for Lymphoid Neoplasms, has died at age 93.

Acalabrutinib and Zanubrutinib for Relapsed MCL

February 2nd 2021

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

February 2nd 2021

MRD Could Prove to Be a Valuable Tool in Multiple Myeloma

February 1st 2021

Marc J. Braunstein, MD, PhD, discusses the current landscape of newly diagnosed multiple myeloma and the utility of minimal residual disease in the research sphere.

Pembrolizumab Approaches EU Approval for Expanded Indication in Relapsed/Refractory Hodgkin Lymphoma

February 1st 2021

February 1, 2020 - The European Medicines Agency’s Committee of Medicinal Products for Human Use has recommended a label expansion for pembrolizumab for use as a single agent in adult and pediatric patients aged 3 years and older with relapsed/refractory classical Hodgkin lymphoma for whom autologous stem cell transplant has failed or following at least 2 previous therapies when ASCT is not an option.

Influencing Factors to Initially Targeting BCMA in MM

February 1st 2021

Management of AML: FLT3 Inhibitors and BCL2 Inhibitors

February 1st 2021

Ongoing Approaches Toward Targeting BCMA

February 1st 2021

Next Steps for Use of Belantamab in Clinical Practice

February 1st 2021

Role of FLT3 Inhibitors in Chemo-Ineligible AML

February 1st 2021

Selinexor Approaches EU Approval for Refractory Multiple Myeloma

January 30th 2021

January 29, 2021 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for selinexor for use in combination with dexamethasone in the treatment of select adult patients with refractory multiple myeloma.

Dr. Jabbour on the Rationale to Evaluate KO-539 in Relapsed/Refractory AML

January 29th 2021

Elias Jabbour, MD, discusses the rationale to evaluate KO-539 in relapsed/refractory acute myeloid leukemia.

Third and Subsequent Line Options for Multiple Myeloma

January 29th 2021

Updates in Relapsed/Refractory Myeloma

January 29th 2021

DLBCL: Treatment Considerations for Challenging Populations

January 29th 2021

Updates in Multiple Myeloma in the Frontline Setting

January 29th 2021

DLBCL: Circumstances for Deviating Away From R-CHOP

January 29th 2021

RRMM: Incorporating INN Melphalan Flufenamide Into Clinical Practice

January 28th 2021

RRMM: INN Melphalan Flufenamide After Alkylator Therapy

January 28th 2021

Role of MRD Testing in Acute Lymphoblastic Leukemia

January 28th 2021